Atha Energy Makes Major New High-Grade Discovery along the Lac 50 Corridor – Intersects 11.5 m of Composite Uranium Mineralization Including 1.6 m of Near Continuous High-Grade 4 km Along Strike from Lac 50 Deposit Area 
3DG Holdings Announces Opening of First ‘Ultimate Luxury Shop’ in Hong Kong at YOHO Mall 
China-France Cultural Dialogue Highlights Research on the Overseas Dissemination of Xi Jinping: The Governance of China V 
GMG Board Approves Capital for Engineering of Factory for Graphene Factories 
Phoenitron Enters Intelligent Fire Protection Sector via CyberMirage’s Strategic Cooperation Framework Agreement Pantaleon and C3 AI Partner to Modernize Sugar Industry, Transforming Harvesting Operations
Top global sugar producer projects up to $5 million benefit using C3 Generative AI REDWOOD…
LAPIX Therapeutics Inc. Announces FDA Clearance of IND Application for its Treg-expanding Tim3/4 Agonist LPX-TI641 to Treat Multiple Sclerosis
BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) — LAPIX Therapeutics, Inc. (“LAPIX”), a biopharmaceutical company focused…
LAPIX Therapeutics Inc. Announces FDA Clearance of IND Application for its Treg-expanding Tim3/4 Agonist LPX-TI641 to Treat Multiple Sclerosis
BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) — LAPIX Therapeutics, Inc. (“LAPIX”), a biopharmaceutical company focused…
Harvard Bioscience and Etisense Announce Agreement for Supply and Distribution of DECRO Miniature Telemetry Jacket Platform for Pre-Clinical Research
Includes dedicated version for integration with Ponemah data management software from Data Sciences International (DSI)…
Harvard Bioscience and Etisense Announce Agreement for Supply and Distribution of DECRO Miniature Telemetry Jacket Platform for Pre-Clinical Research
Includes dedicated version for integration with Ponemah data management software from Data Sciences International (DSI)…
Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company
AI-powered target discovery for a bacterial pathogen with a high medical need where no vaccine…
Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company
AI-powered target discovery for a bacterial pathogen with a high medical need where no vaccine…
Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference
CORAL GABLES, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX),…
Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference
CORAL GABLES, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX),…
Aruna Bio Announces Presentation on the Mechanism of its Neural Exosome Platform and Lead Program, AB126, at the BioProcess International Conference & Exhibition
– AB126, an unmodified exosome derived from neural stem cells, shows native therapeutic activity with anti-inflammatory…
Aruna Bio Announces Presentation on the Mechanism of its Neural Exosome Platform and Lead Program, AB126, at the BioProcess International Conference & Exhibition
– AB126, an unmodified exosome derived from neural stem cells, shows native therapeutic activity with anti-inflammatory…
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)
– Topline results from this study are expected in early Q1 2024 – Celltrion has…
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)
– Topline results from this study are expected in early Q1 2024 – Celltrion has…
Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
Research will use Myriad’s high-definition MRD testing platform based on whole-genome sequencing SALT LAKE CITY,…
Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
Research will use Myriad’s high-definition MRD testing platform based on whole-genome sequencing SALT LAKE CITY,…
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
Full ENVASARC accrual expected in Q4 and final data expected in mid-2024 SAN DIEGO, Sept….
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
Full ENVASARC accrual expected in Q4 and final data expected in mid-2024 SAN DIEGO, Sept….
Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs
– Seasoned biopharma medical leader joins Apnimed as it initiates its Phase 3 clinical program…
Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs
– Seasoned biopharma medical leader joins Apnimed as it initiates its Phase 3 clinical program…
Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library
Planegg/Martinsried, September 18, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology…